Maya M. Zeineddine

Maya M. Zeineddine

Auto-generated profile, based on publicly available information

Maya M. Zeineddine

Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
BBBassem I Beirut
Bassem I Beirut
MSMohamad Ali Sahraian
Mohamad Ali Sahraian
NANabil El Ayoubi
Nabil El Ayoubi
HTHani Tamim
Hani Tamim
JNJohnny Nicolas
Johnny Nicolas
MZMaya M Zeineddine
Maya M Zeineddine

1 December 2015 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
BYBassem I. Yamout
Bassem I. Yamout
MZMaya M. Zeineddine
Maya M. Zeineddine
HTHani Tamim
Hani Tamim
SKSamia J. Khoury
Samia J. Khoury

1 August 2015 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
BYBassem I. Yamout
Bassem I. Yamout
MZMaya M. Zeineddine
Maya M. Zeineddine
RSRaja A. Sawaya
Raja A. Sawaya
SKSamia J. Khoury
Samia J. Khoury

9 January 2020 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
PDF file
MZMaya M Zeineddine
Maya M Zeineddine
BYBassem I Yamout
Bassem I Yamout
Multiple sclerosis was long considered a relatively rare entity in the Middle East, but research over the past 10 years and the publication of the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis guidelines for multiple sclerosis have allowed diagnosis and treatment to occur more efficiently. Most of the first and second-line disease-modifying therapies approved by the Food and Drug Administration and the European Medicine Agency are available in the Middle East. However, the availability of disease-modifying therapies is quite variable, with some countries having access to all multiple sclerosis disease-modifying therapies, while in others there is only one therapeutic option. Economic limitations remain a challenge for the management of multiple sclerosis, especially in countries of war. Moreover, the burden of multiple sclerosis treatment in Syrian and Palestinian refugees is likely high due to the non-availability of funds to cover the high cost of disease-modifying therapies.

1 November 2019 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
NJNesreen Jaafar
Nesreen Jaafar
MZMaya Zeineddine
Maya Zeineddine
JMJoelle Massouh
Joelle Massouh
BBBassem I Beirut
Bassem I Beirut

1 May 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
BBBassem I Beirut
Bassem I Beirut
JMJ. Massouh
J. Massouh
IHI. Hushaymi
I. Hushaymi
MZM. Zeineddine
M. Zeineddine
GSG. Saab
G. Saab